Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Zhuoli Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5243-4001; OpenAlex author ID A5101814280; NIH RePORTER profile ID 10644753. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 14)
Trials
0
Grants
1
Labs led
3
Collaborators
43
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 6 papers · 2020: 7 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 grant

Papers 24

  1. Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review. Last author DOI 10.21037/atm-23-1882↗
  2. Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer. Last author DOI 10.3390/ijms252212038↗
  3. Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Inve… Last author DOI 10.1016/j.acra.2020.04.026↗
  4. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic canc… Last author DOI 10.1080/2162402x.2021.1875638↗
  5. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Last author DOI 10.1016/j.jcyt.2019.12.001↗
  6. MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-020-02246-7↗
  7. Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.1186/s40644-020-0288-3↗
  8. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2019.11205↗
  9. Dinaciclib prolongs survival in the LSL-Kras G12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma. Last author PMID 32269732↗
  10. Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK i… Last author PMID 32509212↗
  11. Effect of route of administration on the efficacy of dendritic cell vaccine in PDAC mice. Co-author PMID 33294276↗
  12. Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies. Last author DOI 10.1016/j.prp.2019.152691↗
  13. MRI Assessment of Associations between Brown Adipose Tissue and Cachexia in Murine Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4172/2165-8048.1000301↗
  14. Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models. Last author PMID 30949410↗
  15. Association of radiomic imaging features and gene expression profile as prognostic factors in pancreatic ductal adenocarcinoma. Co-author PMID 31396352↗
  16. Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a Kras LSL-G12D p53LSL-R172H Pdx1-Cre mouse model. Last author PMID 31497356↗
  17. Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma. Last author PMID 31815046↗
  18. CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery. Last author DOI 10.1097/md.0000000000002664↗
  19. A c(RGDfE) conjugated multi-functional nanomedicine delivery system for targeted pancreatic cancer therapy. Co-author DOI 10.1039/c4tb01402b↗
  20. Quantitative functional MRI in a clinical orthotopic model of pancreatic cancer in immunocompetent Lewis rats. Co-author PMID 26550449↗
  21. Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Co-author DOI 10.2217/nnm.13.72↗
  22. Quantitative magnetization transfer MRI of desmoplasia in pancreatic ductal adenocarcinoma xenografts. First author DOI 10.1002/nbm.3004↗
  23. Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles. First author DOI 10.2147/ijn.s47585↗
  24. Magnetization transfer MRI in pancreatic cancer xenograft models. First author DOI 10.1002/mrm.24127↗

Grants 1

  1. Developing MRI-Guided Preventive Dendritic Cell Vaccination Strategy to Avoid Post-surgical Pancreatic Cancer Recurrence and Metastasis R01CA209886↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vahid Yaghmai · 13 shared papers, 1 shared grant, 2019–2026 · strength 2.96
  2. Aydın Eresen · 13 shared papers, 2019–2024 · strength 1.72
  3. Jia Ying Yang · 13 shared papers, 2019–2021 · strength 1.44
  4. Al B. Benson · 5 shared papers, 2019–2021 · strength 0.57
  5. Zigeng Zhang · 2 shared papers, 2024 · strength 0.46
  6. Guangbo Yu · 2 shared papers, 2024 · strength 0.46
  7. Su Hu · 4 shared papers, 2019–2020 · strength 0.38
  8. Liang Pan · 4 shared papers, 2019–2020 · strength 0.36
  9. Su Hu · 3 shared papers, 2020 · strength 0.32
  10. Andrew C. Larson · 6 shared papers, 2012–2015 · strength 0.27
  11. Wei Chen · 2 shared papers, 2020 · strength 0.23
  12. Weiguo Li · 5 shared papers, 2012–2015 · strength 0.22
  13. Jingjing Xiao · 2 shared papers, 2019–2020 · strength 0.18
  14. Yaqi Zhang · 2 shared papers, 2019 · strength 0.17
  15. Reed A. Omary · 4 shared papers, 2012–2014 · strength 0.17
  16. Jiali Yang · 1 shared paper, 2020 · strength 0.13
  17. Ke Li · 1 shared paper, 2020 · strength 0.13
  18. Jiafei Chen · 1 shared paper, 2020 · strength 0.13
  19. Yumin Li · 1 shared paper, 2020 · strength 0.11
  20. Anna Junjie Shangguan · 1 shared paper, 2020 · strength 0.10
  21. Ke Li · 1 shared paper, 2020 · strength 0.09
  22. Lian Li · 1 shared paper, 2020 · strength 0.09
  23. Li Yu · 1 shared paper, 2019 · strength 0.09
  24. Su Hu · 1 shared paper, 2019 · strength 0.09
  25. Dong‐Hyun Kim · 2 shared papers, 2013–2015 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.